Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 585,807 shares, a decrease of 29.8% from the November 15th total of 834,187 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average daily volume of 1,213,946 shares, the days-to-cover ratio is currently 0.5 days.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OHRP. Wedbush Securities Inc. purchased a new position in shares of Ohr Pharmaceuticals in the third quarter valued at approximately $311,000. Garrison Bradford & Associates Inc. lifted its position in shares of Ohr Pharmaceuticals by 482.4% in the third quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 412,000 shares in the last quarter. Cannell Peter B & Co. Inc. purchased a new position in shares of Ohr Pharmaceuticals in the second quarter valued at approximately $187,000. Renaissance Technologies LLC lifted its position in shares of Ohr Pharmaceuticals by 242.3% in the first quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock valued at $191,000 after acquiring an additional 162,600 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Ohr Pharmaceuticals by 0.7% in the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after acquiring an additional 5,481 shares in the last quarter. Institutional investors and hedge funds own 8.40% of the company’s stock.

OHRP has been the topic of several research reports. Roth Capital initiated coverage on Ohr Pharmaceuticals in a research report on Monday, November 27th. They issued a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research upgraded Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Wednesday, October 25th. Finally, ValuEngine upgraded Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st.

Ohr Pharmaceuticals (NASDAQ:OHRP) opened at $1.58 on Friday. Ohr Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $1.90.

WARNING: “Ohr Pharmaceuticals, Inc. (OHRP) Short Interest Update” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/16/ohr-pharmaceuticals-inc-ohrp-short-interest-update.html.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.